Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats (Q43993131)

28 November 2017

title

Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats (English)

1 reference

28 November 2017

0 references

Kiyoshi Ichikawa

1

1 reference

28 November 2017

Tokuhisa Yamato

2

1 reference

28 November 2017

Kazuma Ojima

3

1 reference

28 November 2017

Atsutoshi Tsuji

4

1 reference

28 November 2017

Kohtaro Ishikawa

5

1 reference

28 November 2017

Hiroshi Kusama

6

1 reference

28 November 2017

Masami Kojima

7

1 reference

28 November 2017

publication date

1 May 2002

1 reference

Clinical and Experimental Pharmacology and Physiology

28 November 2017

published in

1 reference

28 November 2017

volume

29

1 reference

28 November 2017

issue

5-6

1 reference

28 November 2017

page(s)

423-427

1 reference

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

Effect of a non-sulphonylurea hypoglycaemic agent, KAD-1229 on hormone secretion in the isolated perfused pancreas of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

Streptozotocin and alloxan induce DNA strand breaks and poly(ADP–ribose) synthetase in pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.2002.03682.X

10.1046/J.1440-1681.2002.03682.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference